Abstract
Space-occupying lesions of the lacrimal gland and its fossa constitute approximately 5–13% of orbital masses upon biopsy (Shields et al., Arch Ophthalmol 102:1606–1611, 1984; Reese, Trans Ophthalmol Soc UK 91:85–104, 1971; Kennedy, Trans Am Ophthalmol Soc 82:134–157, 1984). Based primarily on Reese’s (Am J Ophthalmol 41:3–11, 1956) 1956 clinicopathologic survey of 112 consecutive expanding lesions of the lacrimal gland, most authorities generally report that approximately 50% of the lesions originate from epithelial elements of the lacrimal gland and 50% are of nonepithelial origin (Font and Gamel, Adenoid cystic carcinoma of the lacrimal gland: a clinicopathologic study of 79 cases. In Nicholson DH (ed). Ocular pathology update. Mason, New York, pp 271–275, 1980; Goder, Orbit 1:91–96, 1982; Rootman, Diseases of the orbit: a multidisciplinary approach. JB Lippincott, Philadelphia, pp 384–405, 1988). Of nonepithelial lesions, 50% are lymphoid tumors and 50% are comprised of various infections and inflammatory conditions. Among the epithelial tumors of the lacrimal gland, approximately 50% are pleomorphic adenomas (benign mixed tumors), 25% are adenoid cystic carcinoma, while the remaining tumors are composed of other types of carcinoma. Information from clinical history, physical examination, and diagnostic imaging, including ultrasonography, computed tomography, and magnetic resonance imaging, form the foundation in determining which category of disease the lacrimal gland tumor belongs. Proper differentiation between lacrimal gland neoplasms is of paramount importance as several of the lesions are life-threatening. The intent of this chapter is to review the clinical characteristics, pertinent diagnostic and pathologic features, biological behavior, and conventional management protocols for the more common epithelial lacrimal gland tumors. A new treatment paradigm for adenoid cystic carcinoma will also be highlighted, as well as the basic science research underlying the advances in the development of targeted anticancer therapies.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Shields JA, Bakewell B, Augsburger JJ, Flanagan JC. Classification and incidence of space-occupying lesions of the orbit: a survey of 645 biopsies. Arch Ophthalmol. 1984;102:1606–11.
Reese AB. Expanding lesions of the orbit. Bowman Lecture. Trans Ophthalmol Soc UK. 1971;91:85–104.
Kennedy RE. An evaluation of 820 orbital cases. Trans Am Ophthalmol Soc. 1984;82:134–57.
Reese AB. The treatment of expanding lesions of the orbit: with particular regard to those arising in the lacrimal gland. The Seventh Arthur J Bedell Lecture. Am J Ophthalmol. 1956;41:3–11.
Font RL, Gamel JW. Adenoid cystic carcinoma of the lacrimal gland: a clinicopathologic study of 79 cases. In: Nicholson DH, editor. Ocular pathology update. New York: Mason; 1980. p. 271–5.
Goder GJ. Tumours of the lacrimal gland. Orbit. 1982;1:91–6.
Rootman J. Diseases of the orbit: a multidisciplinary approach. Philadelphia: JB Lippincott; 1988. p. 384–405.
Shields CL, Shields JA, Eagle RC, Rathwell JP. Clinicopathologic review of 142 cases of lacrimal gland lesions. Ophthalmologica. 1989;96:431–5.
Jakobiec FA, Font RL. Orbit. In: Spencer WH, editor. Ophthalmic pathology: an atlas and textbook. 3rd ed. Philadelphia: WB Saunders; 1986. p. 2496–525.
Stewart WB, Krohel GB, Wright JE. Lacrimal gland and fossa lesions: an approach to diagnosis and management. Ophthalmology. 1979;86:886–95.
Wright JE, Ross GE, Garner A. Primary malignant neoplasms of the lacrimal gland. Br J Ophthalmol. 1992;76:401.
Hurwitz JJ. A practical approach to the management of lacrimal gland lesions. Ophthalmic Surg. 1982;13:829.
Wright JE, Stewart WB, Krohel GB. Clinical presentation and management of lacrimal gland tumours. Br J Ophthalmol. 1979;63:600–6.
Font RL, Smith SL, Bryan RG. Malignant epithelial tumors of the lacrimal gland: a clinicopathologic study of 21 cases. Arch Ophthalmol. 1998;116:613–6.
Ni C, Cheng SC, Dryja TP, Cheng TY. Lacrimal gland tumors: a clinicopathological analysis of 160 cases. Int Ophthalmol Clin. 1982;22:99–120.
Auran J, Jakobiec FA, Krebs W. Benign mixed tumor of the palpebral lobe of the lacrimal gland. Ophthalmology. 1988;95:90–9.
Bech K, Jensen OA. Mixed tumor of the lower orbital region. Arch Ophthalmol. 1965;74:226–8.
Mueller EC, Borit A. Aberrant lacrimal gland and pleomorphic adenoma within the muscle cone. Ann Ophthalmol. 1979;11:661–3.
Mindlin A, Lambert D, Barsky D. Mixed lacrimal gland tumor arising from ectopic lacrimal gland tissue in the orbit. J Pediatr Ophthalmol. 1977;14:44–7.
Murphy MB, Rodriques MM. Benign mixed tumor of the (palpebral) lacrimal gland presenting as a nodular eyelid lesion. Am J Ophthalmol. 1974;77:108–11.
Jakobiec FA, Yeo JH, Trokel SL, et al. Combined clinical and computed tomographic diagnosis of primary lacrimal fossa lesions. Am J Ophthalmol. 1982;94:785–807.
Jakobiec FA, Font, RL. Orbit. In: Spencer WH, Font RL, Green WR, et al, eds. Ophthalmic pathology. An atlas and textbook. 3. Philadelphia: WB Saunders; 1986:2459–2860.
Wright JE, Stewart WB, Krohel GB. Clinical presentation and management of lacrimal gland tumors. Br J Ophthalmol. 1979;63:600–6.
Rootman J, Robertson WD. Tumors. In: Rootman J, editor. Diseases of the orbit. Philadelphia: JB Lippincott; 1988.
Font RL, Gamel JW. Epithelial tumors of the lacrimal gland: analysis of 265 cases. In: Jakobiec FA, editor. Ocular and adnexal tumors. Birmingham: Aesculapius; 1978. p. 787–805.
McPherson SD Jr. Mixed tumor of the lacrimal gland: in a seven-year-old boy. Am J Ophthalmol. 1966;61:561–3.
Rose ER, Wright JE. Pleomorphic adenoma of the lacrimal gland. Br J Ophthalmol. 1992;76:395.
Tse DT, Folberg R. Technique for incisional biopsy of a lacrimal gland mass when the diagnosis of benign mixed tumor cannot be excluded clinically. Ophthalmic Surg. 1988;19:321–4.
Bolzoni A, Pianta L, Farina D, Nicolai P. Benign myoepithelioma of the lacrimal gland: report of a case. Eur Arch Otorhinolaryngol. 2005;262:186–8.
Font RL, Garner A. Myoepithelioma of the lacrimal gland: report of a case with spindle cell morphology. Br J Ophthalmol. 1992;76:634–6.
Grossniklaus HE, Wojno TH, Wilson MW, Someren AO. Myoepithelioma of the lacrimal gland. Arch Ophthalmol. 1997;115:1588–90.
Biggs SL, Font RL. Oncocytic lesions of the caruncle and other ocular adnexa. Arch Ophthalmol. 1977;95:474–8.
Bonavolonta G, Tranfa F, Staibano S, et al. Warthin tumor of the lacrimal gland. Am J Ophthalmol. 1997;124:857–8.
Wright JE. Factors affecting the survival of patients with lacrimal gland tumours. Can J Ophthalmol. 1982;17:3–9.
Lee DA, Campbell RJ, Waller RR, et al. A clinicopathologic study of primary adenoid cystic carcinoma of the lacrimal gland. Ophthalmology. 1985;92:128–34.
Gamel JW, Font RL. Adenoid cystic carcinoma of the lacrimal gland: the clinical significance of a basaloid histologic pattern. Hum Pathol. 1982;13:219–25.
Tellado MV, McLean JW, Specht CS, Varga J. Adenoid cystic carcinoma s of the lacrimal gland in childhood and adolescence. Ophthalmology. 1997;104:1622–5.
Tse DT, Benedetto P, Dubovy S, et al. Clinical analysis of the effect of intraarterial cytoreductive chemotherapy in the treatment of lacrimal gland adenoid cystic carcinoma. Am J Ophthalmol. 2006;141:44–53.
Shields JA, Shields CL, Eagle RC Jr, et al. Adenoid cystic carcinoma developing in the nasal orbit. Am J Ophthalmol. 1997;123:398–9.
Shields JA, Shields CL, Eagle RC Jr, et al. Adenoid cystic carcinoma of the lacrimal gland simulating a dermoid cyst in a 9-year-old boy. Arch Ophthalmol. 1998;116:1673–6.
Wharton JACL, O’Donnell BA. Unusual presentations of pleomorphic adenoma and adenoid cystic carcinoma of the lacrimal gland. Aust N Z J Ophthalmol. 1999;27:145–8.
Duke TG, Fahy GT, Brown LJR. Adenoid cystic carcinoma of the superonasal conjunctival fornix. Orbit. 2000;19:31–5.
Henderson JW, Campell RJ, Farrow GM, Garrity JA. Orbital tumors. 3rd ed. New York: Raven Press Ltd; 1994. p. 323–42.
Kiratli H, Bilgic S. An unusual clinical course of adenoid cystic carcinoma of the lacrimal gland. Orbit. 1999;18:197–201.
Günalp I, Gündüz K. Epithelial tumors of the lacrimal gland. Orbit. 1994;13:147–54.
Byers RM, Berkeley RG, Luna M, Jesse RH. Combined therapeutic approach to malignant lacrimal gland tumors. Am J Ophthalmol. 1975;79:53–5.
Henderson JW, Neault RW. En bloc removal of intrinsic neoplasms of the lacrimal gland. Am J Ophthalmol. 1976;82:905–9.
Rootman J, Lapointe JS. Tumors of the lacrimal gland. In: Rootman J, editor. Diseases of the orbit. A multidisciplinary approach. Philadelphia: JB Lippincott; 1988. p. 384–95.
Marsh JL, Wise DM, Smith M, Schwartz H. Lacrimal gland adenoid cystic carcinoma: intracranial and extracranial en bloc resection. Plast Reconstr Surg. 1981;68:577–85.
Janecka I, Housepian E, Trokel S, et al. Surgical management of malignant tumors of the lacrimal gland. Am J Surg. 1984;148:539–41.
Saini JS, Mohan K, Khandalavala B. Primary radiotherapy in adenoid cystic carcinoma of the lacrimal gland. Orbit. 1990;9:107–11.
Asikin Natanegara IAA, Koornneef L, Veenhof K, et al. An alternative approach for the management of adenocystic carcinoma of the lacrimal gland. Orbit. 1990;9:101–5.
Polito E, Leccisotti A. Epithelial malignancies of the lacrimal gland: survival rates after extensive and conservative therapy. Ann Ophthalmol. 1993;25:422–6.
Tyl JWM, Blank LECM, Koornneef L. Brachytherapy in orbital tumors. Ophthalmology. 1997;104:1475–9.
Buchholz TA, Shimotakahara SG, Weymuller EA Jr, et al. Neutron radiotherapy for adenoid cystic carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 1993;119:747–52.
Douglas JG, Laramore GE, Austin-Seymour M, et al. Treatment of locally advanced adenoid cystic carcinoma of the head and neck with neutron radiotherapy. Int J Radiat Oncol Biol Phys. 2000;46:551–7.
Wolkow N, Jakobiec FA, Lee H, Sutula FC. Long-term outcomes of globe-preserving surgery with proton beam radiation for adenoid cystic carcinoma of the lacrimal gland. Am J Ophthalmol. 2018;195:43–62.
Henderson JW. Adenoid cystic carcinoma of the lacrimal gland, is there a cure? Trans Am Ophthalmol Soc. 1987;85:312–4; discussion 314–319
Henderson JW. Past, present, and future surgical management of malignant epithelial neoplasms of the lacrimal gland. Br J Ophthalmol. 1986;70:727–31.
Ashton N. Epithelial tumours of the lacrimal gland. Mod Probl Ophthalmol. 1975;14:306–23.
Zimmerman LE, Sanders TE, Ackerman LV. Epithelial tumors of the lacrimal gland: prognostic and therapeutic significance of histologic types. Int Ophthalmol Clin. 1962;2:337–67.
Esmaeli B, Ahmadi MA, Youssef A, et al. Outcomes in patients with adenoid cystic carcinoma of the lacrimal gland. Ophthalmic Plast Reconstr Surg. 2004;20:22–6.
Bartley GB, Harris GJ. Adenoid cystic carcinoma of the lacrimal gland: is there a cure…yet? Ophthalmic Plast Reconstr Surg. 2002;18:315–8.
Naugle T Jr, Tepper DJ, Haik BG. Adenoid cystic carcinoma of the lacrimal gland: a case report. Ophthalmic Plast Reconstr Surg. 1994;10:45–8.
Meldrum ML, Tse DT, Benedetto P. Neoadjuvant intracarotid chemotherapy for treatment of advanced adenocystic carcinoma of the lacrimal gland. Arch Ophthalmol. 1998;116:315–21.
Sessions RB, Lehane DE, Smith RJ, et al. Intra-arterial cisplatin treatment of adenoid cystic carcinoma. Arch Otolaryngol. 1982;108:221–4.
Suen JY, Johns ME. Chemotherapy for salivary gland cancer. Laryngoscope. 1982;92:235–9.
Tsukuda M, Kokatsu T, Ito K, et al. Chemotherapy for recurrent adeno- and adenoid cystic carcinomas in the head and neck. J Cancer Res Clin Oncol. 1993;119:756–8.
Schramm VL Jr, Srodes C, Myers EN. Cisplatin therapy for adenoid cystic carcinoma. Arch Otolaryngol. 1981;107:739–41.
Kaplan MJ, Johns ME, Cantrell RW. Chemotherapy for salivary gland cancer. Otolaryngol Head Neck Surg. 1986;95:165–70.
Venook AP, Tseng A Jr, Meyers FJ, et al. Cisplatin, doxorubicin, and 5-fluorouracil chemotherapy for salivary gland malignancies: a pilot study of the Northern California Oncology Group. J Clin Oncol. 1987;5:951–5.
Finkelstein SD, Marsh W, Demetris AJ, et al. Microdissection-based allelotyping discriminates de novo tumor from intrahepatic spread in hepatocellular carcinoma. Hepatology. 2003;37:871–9.
Rolston R, Sasatomi E, Hunt J, et al. Distinguishing de novo second cancer formation from tumor recurrence: mutational fingerprinting by microdissection genotyping. J Mol Diagn. 2001;3:129–32.
Cheung O, Kandil H, Moser AJ, et al. Primary duodenal carcinoma showing divergent growth patterns as determined by microdissection-based mutational genotyping. Arch Pathol Lab Med. 2003;127:861–4.
Sasatomi E, Finkelstein SD, Woods JD, et al. Comparison of accumulated allele loss between primary tumor and lymph node metastasis in stage II non-small cell lung carcinoma: implications for the timing of lymph node metastasis and prognostic value. Cancer Res. 2002;62:2681–9.
Chae YK, Chung SY, Davis AA, et al. Adenoid cystic carcinoma: current therapy and potential therapeutic advances based on genomic profiling. Oncotarget. 2015;6(35):37117–34.
von Holstein SL, Fehr A, Persson M, Therkildsen MH, Prause JU, Heegaard S, Stenman G. Adenoid cystic carcinoma of the lacrimal gland: MYB gene activation, genomic imbalances, and clinical characteristics. Ophthalmology. 2013;120(10):2130–8.
Bell D, Sniegowski MC, Wani K, Prieto V, Esmaeli B. Mutational landscape of lacrimal gland carcinomas and implications for treatment. Head Neck. 2016;38(Suppl 1):E724–9.
Sant DW, Tao W, Field MG, Pelaez D, Jin K, Capobianco A, Dubovy SR, Tse DT, Wang G. Whole exome sequencing of lacrimal gland adenoid cystic carcinoma. Invest Ophthalmol Vis Sci. 2017;58(6):BIO240–6.
Lobry C, Oh P, Aifantis I. Oncogenic and tumor suppressor functions of Notch in cancer: it’s NOTCH what you think. J Exp Med. 2011;208:1931–5.
Su BH, Qu J, Song M, et al. NOTCH1 signaling contributes to cell growth, anti-apoptosis and metastasis in salivary adenoid cystic carcinoma. Oncotarget. 2014;5:6885–95.
Dvoriantchikova G, Tao W, Pappas S, et al. Molecular profiling of the developing lacrimal gland reveals putative role of Notch signaling in branching morphogenesis. Invest Ophthalmol Vis Sci. 2017;58:1098–109.
ClinicalTrials.gov. National Library of Medicine (U.S) A study of AL101 in patients with adenoid cystic carcinoma (ACC) bearing activating notch mutations (ACCURACY). 2018. Identifier: NCT03691207. Retrieved from https://www.clinicaltrials.gov/ct2/show/NCT03691207
Tchekmedyian V, Sherman EJ, Dunn L, Tran C, Baxi S, Katabi N, Antonescu CR, Ostrovnaya I, Haque SS, Pfister DG, Ho AL. Phase II study of lenvatinib in patients with progressive, recurrent or metastatic adenoid cystic carcinoma. J Clin Oncol. 2019;37(18):1529–37.
Chau NG, Hotte SJ, Chen EX, et al. A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC. Ann Oncol. 2012;23:1562–70.
Thomson DJ, Silva P, Denton K, et al. Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck. Head Neck. 2015;37:182–7.
Locati LD, Perrone F, Cortelazzi B, et al. A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: translational analyses and clinical impact. Eur J Cancer. 2016;69:158–65.
Ho AL, Dunn L, Sherman EJ, et al. A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma. Ann Oncol. 2016;27:1902–8.
Wong SJ, Karrison T, Hayes DN, et al. Phase II trial of dasatinib for recurrent ormetastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors. Ann Oncol. 2016;27:318–23.
Ho AL, Sherman EJ, Baxi SS, et al. Phase II study of regorafenib in progressive, recurrent/metastatic adenoid cystic carcinoma. J Clin Oncol. 2016;34(suppl 15).; (abstr 6096)
Dillon PM, Petroni GR, Horton BJ, et al. A phase II study of dovitinib in patients with recurrent or metastatic adenoid cystic carcinoma. Clin Cancer Res. 2017;23:4138–45.
Keam B, Kim S-B, Shin SH, et al. Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma. Cancer. 121:2612–7, 20
Doddapaneni R, Tao W, Naranjo A, Nikpoor N, Tse DT, Pelaez D. Fibroblast growth factor receptor 1 (FGFR1) as a therapeutic target in adenoid cysticcarcinoma of the lacrimal gland. Oncotarget. 2019;10(4):480–93.
Heaps RS, Miller NR, Albert DM, et al. Primary adenocarcinoma of the lacrimal gland. Ophthalmology. 1993;100:1856–60.
Jakobiec FA. Tumors of the lacrimal gland and lacrimal sac. In: Symposium on diseases and surgery of the lids, lacrimal apparatus, and orbit. Transactions of the New Orleans academy of ophthalmology. St Louis: CV Mosby; 1982. p. 190–202.
Henderson JW, Farrow GM. Primary malignant mixed tumors of the lacrimal gland. Ophthalmologica. 1980;87:466–75.
Shields JA, Shields CL. Malignant transformation of presumed pleomorphic adenoma of lacrimal gland after 60 years. Arch Ophthalmol. 1987;105:1403–5.
Font RL, Patipa M, Rosenbaum PS, et al. Correlation of computed tomographic and histopathologic features in malignant transformation of benign mixed tumor of lacrimal gland. Surv Ophthalmol. 1990;34:449–52.
Reese AB. Tumors of the eye. 2nd ed. New York: Harper and Row; 1963. p. 485–506.
Dithmar S, Wojno TH, Washington C, Grossniklaus HE. Mucoepidermoid carcinoma of an accessory lacrimal gland with orbital invasion. Ophthal Plast Reconstr Surg. 2000;16:162–6.
Eviatar JA, Hornblass A. Mucoepidermoid carcinoma of the lacrimal gland: 25 cases and a review and update of the literature. Ophthal Plast Reconstr Surg. 1993;9:170–81.
Pulitzer DR, Echert ER. Mucoepidermoid carcinoma of the lacrimal gland. Arch Ophthalmol. 1987;105:1406–9.
Wagoner MD, Chuo N, Gonder JR, et al. Mucoepidermoid carcinoma of the lacrimal gland. Ann Ophthalmol. 1982;14:383–5.
Jang J, Kie JH, Lee SY, Kim SJ, et al. Acinic cell carcinoma of the lacrimal gland with intracranial extension. Ophthal Plast Reconstr Surg. 2001;17:454–7.
De Rosa G, Zeppa P, Tranfa F, Bonavolonta G. Acinic cell carcinoma arising in a lacrimal gland: first case report. Cancer. 1986;57:1988–91.
Hotta K, Arisawa T, Mito H, Narita M. Primary squamous cell carcinoma of the lacrimal gland. Clin Exp Ophthalmol. 2005;33:534–5.
Su GW, Patipa M, Font RL. Primary squamous cell carcinoma arising from an epithelium-lined cyst of the lacrimal gland. Ophthal Plast Reconstr Surg. 2005;21:383–5.
Fenton S, Srinivasan S, Harnett A, Brown I. Squamous cell carcinoma of the lacrimal gland. Eye. 2003;17:424–5.
Shields JA, Shields CL, Epstein JA, Scartozzi R. Primary epithelial malignancies of the lacrimal gland: the 2003 Ramon L. Font lecture. Ophthal Plast Reconstr Surg. 2004;20:10–21.
Chan WM, Liu DTL, Lam LYM, Choi PCL. Primary epithelial-myoepithelial carcinoma of the lacrimal gland. Arch Ophthalmol. 2004;122:1714–7.
Takahira M, Nakamura YM, Shimizu SI, et al. Carcinosarcoma of the lacrimal gland arising from a pleomorphic adenoma. Am J Ophthalmol. 2005;140:337–40.
Ni C, Kuo KP, Dryja KP. Histopathologic classification of 272 primary epithelial tumors of the lacrimal gland. Chin Med J. 1992;105:481–5.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2022 Springer Nature Switzerland AG
About this entry
Cite this entry
Tse, D.T., Latting, M.W., Hui, J.I. (2022). Epithelial Tumors of the Lacrimal Gland. In: Albert, D.M., Miller, J.W., Azar, D.T., Young, L.H. (eds) Albert and Jakobiec's Principles and Practice of Ophthalmology. Springer, Cham. https://doi.org/10.1007/978-3-030-42634-7_68
Download citation
DOI: https://doi.org/10.1007/978-3-030-42634-7_68
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-42633-0
Online ISBN: 978-3-030-42634-7
eBook Packages: MedicineReference Module Medicine